Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis

Germain Honvo,Jean-Yves Reginster,Véronique Rabenda,Anton Geerinck,O. Mkinsi,Alexia Charles,René Rizzoli,Cyrus Cooper,Bernard Avouac,Olivier Bruyère

Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis

2019

Germain Honvo
Jean-Yves Reginster
Véronique Rabenda
Anton Geerinck
O. Mkinsi
Alexia Charles
René Rizzoli
Cyrus Cooper
Bernard Avouac
Olivier Bruyère

Background Symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) are an important drug class in the treatment armamentarium for osteoarthritis (OA).

Keywords:

Physical therapy
Diabetes mellitus
Meta-analysis
MEDLINE
Internal medicine
Osteoarthritis
Drug class
Urinary system
MedDRA
Medicine
Adverse effect
pharmacology toxicology
Intensive care medicine
Pharmacotherapy
treatment outcome

Correction
Source
Cite
Save
Machine Reading By IdeaReader

110

References

Citations